跳至主要内容
临床试验/ACTRN12620000121965
ACTRN12620000121965尚未招募未知

The Role of Vitamin D in Controlling and Reducing Diabetes Mellitus Risks via changes in HbA1c and blood glucose

niversity of Technology, Sydney0 个研究点目标入组 134 人开始时间: 2020年2月10日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
134

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1) Aged greater than or equal to 18 years old; 2) Diagnosed with Type 2 Diabetes in the preceding 12 months, and not on diabetic medication or insulin treatment; 3) Serum 25OHD is between 28 nmol/l and 85 nmol/l and not on vitamin D supplements or any relevant medications; 4) Do not have thyroid diseases, liver impairment, renal failure, cancer, osteoporosis, dementia, mental diseases or taking relevant medications; 5) Not pregnant or breastfeeding women.

排除标准

  • 1) Unable to give written informed consent or follow the instructions in current trial; 2) are already on vitamin D supplementation or relevant diabetes control medications; 3) have liver impairment, renal failure (eGFR <50 ml/min), cancer, osteoporosis, dementia, mental disease, and thyroid diseases including hyperparathyroidism, hypercalcaemia, or taking any relevant medications; 4) are < 18 years old or are pregnant or breastfeeding women. 5) are vegen and can not ingest any animal product.

研究者

发起方
niversity of Technology, Sydney

相似试验